Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 313

1.

New treatment strategies for ulcerative colitis.

Panés J, Alfaro I.

Expert Rev Clin Immunol. 2017 Jun 21:1-11. doi: 10.1080/1744666X.2017.1343668. [Epub ahead of print]

PMID:
28617055
2.

Increasing efficiency of MRE for diagnosis of Crohn's disease activity through proper sequence selection: a practical approach for clinical trials.

Rimola J, Alvarez-Cofiño A, Pérez-Jeldres T, Rodríguez S, Alfaro I, Ordás I, Ricart E, Panés J.

Abdom Radiol (NY). 2017 Jun 13. doi: 10.1007/s00261-017-1203-7. [Epub ahead of print]

PMID:
28612164
3.

Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry.

Chaparro M, Ramas M, Benítez JM, López-García A, Juan A, Guardiola J, Mínguez M, Calvet X, Márquez L, Fernández Salazar LI, Bujanda L, García C, Zabana Y, Lorente R, Barrio J, Hinojosa E, Iborra M, Cajal MD, Van Domselaar M, García-Sepulcre MF, Gomollón F, Piqueras M, Alcaín G, García-Sánchez V, Panés J, Domènech E, García-Esquinas E, Rodríguez-Artalejo F, Gisbert JP.

Am J Gastroenterol. 2017 May 23. doi: 10.1038/ajg.2017.96. [Epub ahead of print]

PMID:
28534520
4.

Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents.

Reinisch W, Jahnsen J, Schreiber S, Danese S, Panés J, Balsa A, Park W, Kim J, Lee JU, Yoo DH.

BioDrugs. 2017 Jun;31(3):223-237. doi: 10.1007/s40259-017-0219-4.

5.

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.

Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Panés J; OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators.

N Engl J Med. 2017 May 4;376(18):1723-1736. doi: 10.1056/NEJMoa1606910.

PMID:
28467869
6.

Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn's Disease: Efficacy in a Single-Centre Cohort.

López-García A, Rovira M, Jauregui-Amezaga A, Marín P, Barastegui R, Salas A, Ribas V, Feu F, Elizalde JI, Fernández-Avilés F, Martínez C, Gutiérrez G, Rosiñol L, Carreras E, Urbano A, Lozano M, Cid J, Suárez-Lledó M, Masamunt MC, Comas D, Giner A, Gallego M, Alfaro I, Ordás I, Panés J, Ricart E.

J Crohns Colitis. 2017 Apr 13. doi: 10.1093/ecco-jcc/jjx054. [Epub ahead of print]

PMID:
28419282
7.

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.

Feagan BG, Sandborn WJ, D'Haens G, Panés J, Kaser A, Ferrante M, Louis E, Franchimont D, Dewit O, Seidler U, Kim KJ, Neurath MF, Schreiber S, Scholl P, Pamulapati C, Lalovic B, Visvanathan S, Padula SJ, Herichova I, Soaita A, Hall DB, Böcher WO.

Lancet. 2017 Apr 29;389(10080):1699-1709. doi: 10.1016/S0140-6736(17)30570-6. Epub 2017 Apr 12.

PMID:
28411872
8.

Association between disease activity and quality of life in ulcerative colitis: Results from the CRONICA-UC study.

Panés J, Domènech E, Aguas Peris M, Nos P, Riestra S, Juliá B, Cea-Calvo L, Romero C, Marín-Jiménez I.

J Gastroenterol Hepatol. 2017 Mar 29. doi: 10.1111/jgh.13795. [Epub ahead of print]

PMID:
28370253
9.

Communication Between Physicians and Patients with Ulcerative Colitis: Reflections and Insights from a Qualitative Study of In-Office Patient-Physician Visits.

Rubin DT, Dubinsky MC, Martino S, Hewett KA, Panés J.

Inflamm Bowel Dis. 2017 Apr;23(4):494-501. doi: 10.1097/MIB.0000000000001048.

PMID:
28296817
10.

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials.

Panés J, Sandborn WJ, Schreiber S, Sands BE, Vermeire S, D'Haens G, Panaccione R, Higgins PDR, Colombel JF, Feagan BG, Chan G, Moscariello M, Wang W, Niezychowski W, Marren A, Healey P, Maller E.

Gut. 2017 Jun;66(6):1049-1059. doi: 10.1136/gutjnl-2016-312735. Epub 2017 Feb 16.

11.

ECCO IBD Curriculum.

Lindsay JO, Irving PM, Mantzaris GJ, Panés J; ECCO Education Committee and ECCO Governing Board.

J Crohns Colitis. 2017 Jan 27. doi: 10.1093/ecco-jcc/jjx004. [Epub ahead of print] No abstract available.

PMID:
28172611
12.

Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus.

Vuitton L, Peyrin-Biroulet L, Colombel JF, Pariente B, Pineton de Chambrun G, Walsh AJ, Panes J, Travis SP, Mary JY, Marteau P.

Aliment Pharmacol Ther. 2017 Mar;45(6):801-813. doi: 10.1111/apt.13948. Epub 2017 Jan 23.

PMID:
28112419
13.

Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade®] or Conventional Therapy.

D'Haens G, Reinisch W, Colombel JF, Panes J, Ghosh S, Prantera C, Lindgren S, Hommes DW, Huang Z, Boice J, Huyck S, Cornillie F; ENCORE investigators.

J Crohns Colitis. 2017 Jun 1;11(6):680-689. doi: 10.1093/ecco-jcc/jjw221.

PMID:
28025307
14.

ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update.

Danese S, Fiorino G, Raine T, Ferrante M, Kemp K, Kierkus J, Lakatos PL, Mantzaris G, van der Woude J, Panes J, Peyrin-Biroulet L.

J Crohns Colitis. 2017 Jan;11(1):26-34. doi: 10.1093/ecco-jcc/jjw198. Epub 2016 Dec 7. No abstract available.

PMID:
27927718
15.

Stem Cell Therapy for Perianal Fistulas in Crohn's Disease.

Panes J.

Gastroenterol Hepatol (N Y). 2016 Oct;12(10):637-640. No abstract available.

16.

Alterations in the epithelial stem cell compartment could contribute to permanent changes in the mucosa of patients with ulcerative colitis.

Dotti I, Mora-Buch R, Ferrer-Picón E, Planell N, Jung P, Masamunt MC, Leal RF, Martín de Carpi J, Llach J, Ordás I, Batlle E, Panés J, Salas A.

Gut. 2016 Nov 1. pii: gutjnl-2016-312609. doi: 10.1136/gutjnl-2016-312609. [Epub ahead of print]

17.

Development of an index to define overall disease severity in IBD.

Siegel CA, Whitman CB, Spiegel BM, Feagan B, Sands B, Loftus EV Jr, Panaccione R, D'Haens G, Bernstein CN, Gearry R, Ng SC, Mantzaris GJ, Sartor B, Silverberg MS, Riddell R, Koutroubakis IE, O'Morain C, Lakatos PL, McGovern DP, Halfvarson J, Reinisch W, Rogler G, Kruis W, Tysk C, Schreiber S, Danese S, Sandborn W, Griffiths A, Moum B, Gasche C, Pallone F, Travis S, Panes J, Colombel JF, Hanauer S, Peyrin-Biroulet L.

Gut. 2016 Oct 25. pii: gutjnl-2016-312648. doi: 10.1136/gutjnl-2016-312648. [Epub ahead of print]

PMID:
27780886
18.

Direct and Indirect Effects of Tofacitinib on Treatment Satisfaction in Patients with Ulcerative Colitis.

Panés J, Su C, Bushmakin AG, Cappelleri JC, Healey P.

J Crohns Colitis. 2016 Nov;10(11):1310-1315. Epub 2016 May 18.

PMID:
27194530
19.

Advances in Use of Endoscopy, Radiology, and Biomarkers to Monitor Inflammatory Bowel Diseases.

Panes J, Jairath V, Levesque BG.

Gastroenterology. 2017 Feb;152(2):362-373.e3. doi: 10.1053/j.gastro.2016.10.005. Epub 2016 Oct 15. Review.

PMID:
27751880
20.

Challenges Faced by Cross-sectional Imaging and Histological Endpoints in Clinical Trials.

Villanacci V, Baert F, Cornillie F, De Hertogh G, Panés J.

J Crohns Colitis. 2017 Mar 1;11(suppl_2):S586-S592. doi: 10.1093/ecco-jcc/jjw161.

PMID:
27651219

Supplemental Content

Support Center